Costs of seasonal influenza vaccine delivery in a pediatric demonstration project for children aged 6–23 months — Nakuru and Mombasa Counties, Kenya, 2019–2021

• Published in: Vaccine 2024-10, Vol.42, p.125519, Article 125519
• Main Authors: Gharpure, Radhika, Akumu, Angela Oloo, Dawa, Jeanette, Gobin, Stacie, Adhikari, Bishwa B., Lafond, Kathryn E., Fischer, Leah S., Mirieri, Harriet, Mwazighe, Henry, Tabu, Collins, Jalang'o, Rose, Kamau, Peter, Silali, Catherine, Kalani, Rosalia, Oginga, Pauline, Jewa, Isaac, Njenga, Virginia, Ebama, Malembe S., Bresee, Joseph S., Njenga, M. Kariuki, Osoro, Eric, Meltzer, Martin I., Emukule, Gideon O.
• Format: Article
• Language: English
• Subjects: Costs; Data collection; Economic impact; Economics; Expenditures; Health care facilities; Health facilities; Immunization; Influenza; Influenza vaccine; Operating costs; Pediatric; Pediatrics; Training; Vaccination; Vaccines; Waste management
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2023.12.029

During November 2019–October 2021, a pediatric influenza vaccination demonstration project was conducted in four sub-counties in Kenya. The demonstration piloted two different delivery strategies: year-round vaccination and a four-month vaccination campaign. Our objective was to compare the costs of both delivery strategies. Cost data were collected using standardized questionnaires and extracted from government and project accounting records. We reported total costs and costs per vaccine dose administered by delivery strategy from the Kenyan government perspective in 2021 US$. Costs were separated into financial costs (monetary expenditures) and economic costs (financial costs plus the value of existing resources). We also separated costs by administrative level (national, regional, county, sub-county, and health facility) and program activity (advocacy and social mobilization; training; distribution, storage, and waste management; service delivery; monitoring; and supervision). The total estimated cost of the pediatric influenza demonstration project was US$ 225,269 (financial) and US$ 326,691 (economic) for the year-round delivery strategy (30,397 vaccine doses administered), compared with US$ 214,753 (financial) and US$ 242,385 (economic) for the campaign strategy (25,404 doses administered). Vaccine purchase represented the largest proportion of costs for both strategies. Excluding vaccine purchase, the cost per dose administered was US$ 1.58 (financial) and US$ 5.84 (economic) for the year-round strategy and US$ 2.89 (financial) and US$ 4.56 (economic) for the campaign strategy. The financial cost per dose was 83% higher for the campaign strategy than the year-round strategy due to larger expenditures for advocacy and social mobilization, training, and hiring of surge staff for service delivery. However, the economic cost per dose was more comparable for both strategies (year-round 22% higher than campaign), balanced by higher costs of operating equipment and monitoring activities for the year-round strategy. These delivery cost data provide real-world evidence to inform pediatric influenza vaccine introduction in Kenya.